How a body grows old.

For most of the history of medicine, aging was treated as background — the thing that happens while diseases are studied. That changed in 2013, when López-Otín and colleagues published "The Hallmarks of Aging" in Cell: a framework naming nine distinct, measurable cellular processes that together produce what we experience as getting old.^[1] The paper became one of the most cited in modern biology because it turned a vague fate into a parts list — and a parts list is something you can, at least in principle, work on.

The 2023 update expanded the list to twelve.^[2] The hallmarks include genomic instability (accumulated DNA damage), telomere attrition (the protective chromosome caps shortening with each cell division), epigenetic alterations (the gene-regulation software drifting), mitochondrial dysfunction (the cell's power plants leaking and underperforming), stem cell exhaustion (repair reservoirs running down), cellular senescence, and chronic inflammation — the last two being the pair this article spends most of its time on, because they are the two that current cell-based and drug interventions most directly target.

Two features of the framework matter for reading anything in longevity medicine. First, the hallmarks are interconnected: DNA damage pushes cells into senescence, senescent cells drive inflammation, inflammation degrades stem cell function. Interventions rarely touch one dial in isolation. Second, each hallmark comes with the same test: aggravating it should accelerate aging, and easing it should slow aging in animal models. That test — not marketing copy — is the standard the rest of this article applies.

In one sentence

Aging, at the cellular level, is the progressive accumulation of damage and dysregulation across roughly twelve interconnected processes — not a single clock, but a set of failing systems that push on one another.

When a cell accumulates enough damage — critically short telomeres, unrepaired DNA breaks, oncogene activation — it faces a fork: die by programmed cell death, or enter senescence, a state in which it permanently stops dividing but stays alive. Senescence begins as protection. A damaged cell that cannot divide cannot become a tumor, which is why the machinery exists and why simply switching it off is not an option.

The problem is what senescent cells do while they linger. In 2008, Judith Campisi's group characterized the senescence-associated secretory phenotype, or SASP: senescent cells secrete a steady stream of inflammatory cytokines, proteases, and growth factors into the tissue around them.^[3] One senescent cell is a managed casualty. Thousands, accumulating in skin, joints, blood-vessel walls, and organs over decades, become a source of chronic tissue damage — degrading the matrix around them, recruiting inflammation, and pushing neighboring healthy cells toward senescence in turn. Campisi's later review gave the double nature its lasting name: the dark side of tumor suppression.

Why do they accumulate? Partly because production rises — an older body generates senescent cells faster. And partly because clearance falls. Senescent cells are supposed to be found and removed by the immune system; natural killer cells recognize the stress ligands senescent cells display and eliminate them, a surveillance system described in detail in this journal's NK cell explainer. With age, that surveillance weakens — so the same decade that produces more senescent cells removes fewer of them. The result is compounding: a slow accumulation that animal work links directly to shortened healthspan.^[5]

Take a blood sample from a healthy twenty-five-year-old and a healthy seventy-five-year-old, with no infection and no diagnosed disease in either, and the older sample will typically show higher levels of inflammatory markers — IL-6, TNF-α, C-reactive protein. In 2000, the Italian immunologist Claudio Franceschi gave this phenomenon its name: inflammaging, the chronic, low-grade, sterile inflammation that develops with age even in the absence of any infection to fight.^[4]

Acute inflammation is a fire brigade: it arrives, does its work, and goes home. Inflammaging is a fire that never quite goes out — and never quite finds anything to burn.

The sources feed each other. Senescent cells secrete inflammatory signals through the SASP. Aging immune cells respond to those signals less precisely, resolving inflammation more slowly. Damaged mitochondria leak molecular fragments that the immune system misreads as bacterial invaders, because mitochondria are, in evolutionary origin, ancient bacteria. Visceral fat tissue secretes its own inflammatory cytokines. Each source amplifies the others — which is exactly the hallmark interconnection from section one, running in the wrong direction.

Why it matters: epidemiology repeatedly finds baseline inflammatory markers among the stronger blood-measurable correlates of frailty, cardiovascular events, and mortality in older adults.^[4] That correlation is what makes inflammaging the most practical target on the list — inflammation, unlike telomere length, is something medicine has real levers on. It is also why immunomodulatory cell therapies aim at it: the mesenchymal stromal cells described in this journal's MSC explainer act largely by damping exactly this kind of dysregulated inflammatory signaling.

The senescence field's defining experiment came from the Mayo Clinic in 2016. Baker and colleagues engineered mice so that senescent cells could be selectively destroyed on command, then aged the animals with the switch on. Median lifespan rose roughly 25 percent; kidneys, hearts, and fat tissue deteriorated more slowly; tumors appeared later.^[5] That result is why senolytics — drugs that push senescent cells into the cell death they escaped — became one of the most funded ideas in aging research. In humans, the field is at the beginning: the first trials showed that a dasatinib-plus-quercetin course reduces senescent-cell burden in human tissue,^[6] which demonstrates the mechanism transfers — but no senolytic has yet shown improved health outcomes in a large randomized trial, and the honest summary is "promising, unproven."

The cell-therapy line of work targets the inflammaging axis instead. In the University of Miami's randomized phase II trial, older adults with aging frailty received a single intravenous infusion of allogeneic mesenchymal stromal cells or placebo. At six months, the treated groups showed improved six-minute walk distance and a significant drop in circulating TNF-α — precisely the inflammatory marker inflammaging elevates — with no treatment-related serious adverse events.^[7] This is the strongest randomized human signal behind the systemic protocols described on our anti-aging program page, and its shape is worth being precise about: a phase II trial in a specific population, with functional and biomarker endpoints. It is evidence of reduced inflammation and improved function — not evidence of extended lifespan, and no therapy on earth currently has that in humans.

What did not work is equally instructive. Young-blood plasma transfusions, marketed briefly in the United States, produced no convincing trial benefit and drew an FDA warning. Telomerase activation remains caught on the tumor-suppression trade-off from section two. The pattern across the field: interventions aimed at a single hallmark in isolation have repeatedly disappointed, while the durable results — exercise most of all — move several hallmarks at once.

Use the science as a filter for the marketing. Nothing sold anywhere today — drug, supplement, or cell infusion — has been shown to extend human lifespan, and a provider claiming otherwise is displaying the red flags catalogued in our article on safety and vetting. What the evidence does support is narrower and still worth having: inflammaging is real and measurable in standard blood work; senescent-cell burden is a genuine driver of tissue aging; and a randomized human trial has shown a single MSC infusion can lower inflammatory markers and improve physical function in frail older adults.^[7]

That framing is how TrueCell physicians present the longevity protocols: systemic infusions aimed at the inflammatory axis of aging, anchored to biomarkers measured before and after — CRP, TNF-α, IL-6 — rather than to promises about the calendar. A protocol that moves your measured inflammatory markers and your measured function has done something real, and something the trial literature says is achievable. A protocol sold as adding years to your life has left the evidence behind.

And the unglamorous part remains true here as everywhere in this journal: exercise is the best-documented multi-hallmark intervention known — it improves mitochondrial function, stem cell activity, and inflammatory tone simultaneously — and it, sleep, and metabolic health are the baseline any honest longevity plan starts from. Cellular medicine, where it is supported, belongs on top of that foundation, not in place of it.